- Home
- NXGL vs TRIB Comparison
NXGL vs TRIB Comparison
Compare NXGL & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- TRIB
- Stock Information
- Founded
- NXGL 1997
- TRIB 1992
- Country
- NXGL United States
- TRIB Ireland
- Employees
- NXGL N/A
- TRIB N/A
- Industry
- NXGL Medical/Dental Instruments
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NXGL Health Care
- TRIB Health Care
- Exchange
- NXGL Nasdaq
- TRIB Nasdaq
- Market Cap
- NXGL 23.8M
- TRIB 25.5M
- IPO Year
- NXGL 2021
- TRIB N/A
- Fundamental
- Price
- NXGL $3.32
- TRIB $0.77
- Analyst Decision
- NXGL
- TRIB
- Analyst Count
- NXGL 0
- TRIB 0
- Target Price
- NXGL N/A
- TRIB N/A
- AVG Volume (30 Days)
- NXGL 66.5K
- TRIB 6.3M
- Earning Date
- NXGL 03-27-2025
- TRIB 04-03-2025
- Dividend Yield
- NXGL N/A
- TRIB N/A
- EPS Growth
- NXGL N/A
- TRIB N/A
- EPS
- NXGL N/A
- TRIB N/A
- Revenue
- NXGL $6,729,000.00
- TRIB $59,126,000.00
- Revenue This Year
- NXGL $115.48
- TRIB $11.63
- Revenue Next Year
- NXGL $49.27
- TRIB $10.13
- P/E Ratio
- NXGL N/A
- TRIB N/A
- Revenue Growth
- NXGL 90.57
- TRIB N/A
- 52 Week Low
- NXGL $1.84
- TRIB $0.73
- 52 Week High
- NXGL $5.10
- TRIB $3.55
- Technical
- Relative Strength Index (RSI)
- NXGL 44.29
- TRIB 43.29
- Support Level
- NXGL $3.06
- TRIB $0.73
- Resistance Level
- NXGL $3.66
- TRIB $0.82
- Average True Range (ATR)
- NXGL 0.26
- TRIB 0.06
- MACD
- NXGL 0.02
- TRIB -0.01
- Stochastic Oscillator
- NXGL 35.37
- TRIB 14.77
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.